Leen Mathys
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leen Mathys has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Holanda Sampaio
Laboratório de Biotecnologia Marinha—BioMar-Lab, Departamento de Engenharia de Pesca, Universidade Federal do Ceará, Campus do Pici s/n, bloco 871, Fortaleza 60440-970, CE, Brazil
1 shared publication - Ana Claudia Silva Gondim
Laboratório de Bioinorgânica, Departamento de Química Orgânica e Inorgânica, Universidade Federal do Ceará, Fortaleza, CE, Brasil
1 shared publication - Benildo Sousa Cavada
BioMol-Lab, Department of Biochemistry and Molecular Biology, Federal University of Ceará, Fortaleza 60440-970, Ceará, Brazil
1 shared publication - Celso Shiniti Nagano
Laboratório de Biotecnologia Marinha—BioMar-Lab, Departamento de Engenharia de Pesca, Universidade Federal do Ceará, Campus do Pici s/n, bloco 871, Fortaleza 60440-970, CE, Brazil
1 shared publication - Cíntia Renata Costa Rocha
Universidade Federal de Pernambuco, Brasil
1 shared publication - Jan Balzarini
Rega Institute of Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium
1 shared publication
Latest Publications
- Open Access
- 14 January 2019
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 10 (3) , 390-398
Potent antiviral activity of carbohydrate-specific algal and leguminous lectins from the Brazilian biodiversity
Brazil has one of the largest biodiversities in the world. The search for new natural products extracted from the Brazilian flora may lead to the discovery of novel drugs with potential to treat infectious and other diseases. Here, we have investigated 9 lectins extracted and purified from the Northeastern Brazilian flora, from both leguminous species: Canavalia brasiliensis (ConBr), C. maritima (ConM), Dioclea lasiocarpa (DLasiL) and D. sclerocarpa (DSclerL), and algae Amansia multifida (AML), Bryothamniom seaforthii (BSL), Hypnea musciformis (HML), Meristiella echinocarpa (MEL) and Solieria filiformis (SfL). They were exposed to a panel of 18 different viruses, including HIV and influenza viruses. Several lectins showed highly potent antiviral activity, often within the low nanomolar range. DSclerL and DLasiL exhibited EC50 values (effective concentration of lectin required to inhibit virus-induced cytopathicity by 50%) of 9 nM to 46 nM for HIV-1 and respiratory syncytial virus (RSV), respectively, DLasiL also inhibited feline corona virus at an EC50 of 5 nM, and DSclerL, ConBr and ConM showed remarkably low EC50 values ranging from 0.4 to 6 nM against influenza A virus strain H3N2 and influenza B virus. For HIV, evidence pointed to the blockage of entry of the virus into its target cells as the underlying mechanism of antiviral action of these lectins. Overall, the most promising lectins based on their EC50 values were DLasiL, DSclerL, ConBr, ConM, SfL and HML. These novel findings indicate that lectins from the Brazilian flora may provide novel antiviral compounds with therapeutic potential.
- 14 January 2019
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 10 (3) , 390-398
Open AccessPotent antiviral activity of carbohydrate-specific algal and leguminous lectins from the Brazilian biodiversity
Brazil has one of the largest biodiversities in the world. The search for new natural products extracted from the Brazilian flora may lead to the discovery of novel drugs with potential to treat infectious and other diseases. Here, we have investigated 9 lectins extracted and purified from the Northeastern Brazilian flora, from both leguminous species: Canavalia brasiliensis (ConBr), C. maritima (ConM), Dioclea lasiocarpa (DLasiL) and D. sclerocarpa (DSclerL), and algae Amansia multifida (AML), Bryothamniom seaforthii (BSL), Hypnea musciformis (HML), Meristiella echinocarpa (MEL) and Solieria filiformis (SfL). They were exposed to a panel of 18 different viruses, including HIV and influenza viruses. Several lectins showed highly potent antiviral activity, often within the low nanomolar range. DSclerL and DLasiL exhibited EC50 values (effective concentration of lectin required to inhibit virus-induced cytopathicity by 50%) of 9 nM to 46 nM for HIV-1 and respiratory syncytial virus (RSV), respectively, DLasiL also inhibited feline corona virus at an EC50 of 5 nM, and DSclerL, ConBr and ConM showed remarkably low EC50 values ranging from 0.4 to 6 nM against influenza A virus strain H3N2 and influenza B virus. For HIV, evidence pointed to the blockage of entry of the virus into its target cells as the underlying mechanism of antiviral action of these lectins. Overall, the most promising lectins based on their EC50 values were DLasiL, DSclerL, ConBr, ConM, SfL and HML. These novel findings indicate that lectins from the Brazilian flora may provide novel antiviral compounds with therapeutic potential.